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Background
HIV Gag specific CD4+ and CD8+ T cell responses are
important for HIV immune control. Pulsing overlapping
Gag peptides on autologous cells (Opal) has proven
immunogenic and effective in reducing viral loads in mul-
tiple macaque studies, warranting clinical evaluation.
Methods
We performed a phase I, single centre, placebo-controlled,
double-blinded and dose-escalating study to evaluate the
safety and preliminary immunogenicity of a novel vaccine
approach Opal-HIV-Gag(c). This vaccine is constituted by
120 15mer peptides, overlapping by 11 amino acids span-
ning the entire HIV Gag C Durban consensus sequence
proteome, pulsed on white blood cells enriched from
whole blood using a closed system, followed by intrave-
nously reinfusion. Patients with well controlled HIV on
HAART received four vaccinations administered at week
0, 4, 8 and 12, and were followed up for 12 weeks post-
treatment. Eighteen people were enrolled in three groups:
12mg (n=6), 24mg (n=6) or matching placebo (n=6). An
additional group (48mg, n=2) was not evaluable. Immuno-
genicity was assessed by IFNg ELIspot/ICS.
Results
The constituent peptides in Opal-HIV-Gag(c) were anti-
genic in vitro using peptide stimulated PBMCs (median
30 fold increase). However, after vaccination with Opal-
HIV-Gag(c), 1/6 at 12mg and 1/6 at 24mg had a 2 to 3
fold increase from Baseline of Gag specific CD8+ T cells
at Week 14, compared to 0/6 placebo recipients. No Gag
specific CD4+ T cell responses or overall change in Rev,
Nef, Tat and CMV specific responses were detected.
Marked, transient and self-limiting lymphopenia was
observed immediately post-vaccination (4 hours) in
Opal-HIV-Gag(c) but not placebo recipients, with med-
ian 1.72 to 0.67 million lymphocytes/mL for active
groups (P<0.001), compared to 1.70 to 1.56 for placebo
group (P=0.16).
Conclusion
Despite the promising effect found in several Macaca
nemestrina studies using this approach, Opal-HIV-Gag
(c) was not significantly immunogenic in this population
and improved methods of generating Gag-specific T-cell
responses are required.
Author details
1University of Oxford, Oxford, UK. 2St Stephens Clinic Chelsea and
Westminister Hospital, London, UK. 3Medicines Development Limited,
Melbourne, Australia. 4Imperial College London, IAVI Human Immunology
Laboratory, London, UK. 5Imperial College Healthcare, London, UK. 6Ragon
Insitute, Boston, USA. 7GlobalBiosolutions, Craigieburn, Australia. 8Oxford
University, Paediatrics, Oxford, UK.
Published: 13 September 2012
doi:10.1186/1742-4690-9-S2-P115
Cite this article as: Kløverpris et al.: Immune response after vaccination of
HIV infected individuals receiving HAART with overlapping gag peptides
pulsed on autologous cells. Retrovirology 2012 9(Suppl 2):P115.
1University of Oxford, Oxford, UK
Full list of author information is available at the end of the article
Kløverpris et al. Retrovirology 2012, 9(Suppl 2):P115
http://www.retrovirology.com/content/9/S2/P115
© 2012 Kløverpris et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
